Porta C - Search Results

1

Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed.

Bertino P, Porta C, Barbone D, Germano S, Busacca S, Pinato S, Tassi G, Favoni R, Gaudino G, Mutti L. Bertino P, et al. Among authors: porta c. Thorax. 2007 Aug;62(8):690-5. doi: 10.1136/thx.2006.069872. Epub 2007 Feb 20. Thorax. 2007. PMID: 17311837 Free PMC article.

2

The presence of simian-virus 40 sequences in mesothelioma and mesothelial cells is associated with high levels of vascular endothelial growth factor.

Cacciotti P, Strizzi L, Vianale G, Iaccheri L, Libener R, Porta C, Tognon M, Gaudino G, Mutti L. Cacciotti P, et al. Among authors: porta c. Am J Respir Cell Mol Biol. 2002 Feb;26(2):189-93. doi: 10.1165/ajrcmb.26.2.4673. Am J Respir Cell Mol Biol. 2002. PMID: 11804869

3

Intrapleural interleukin-2 induces nitric oxide production in pleural effusions from malignant mesothelioma: a possible mechanism of interleukin-2-mediated cytotoxicity?

Porta C, Rizzo V, Zimatore M, Sartore-Bianchi A, Danova M, Mutti L. Porta C, et al. Lung Cancer. 2002 Nov;38(2):159-62. doi: 10.1016/s0169-5002(02)00187-3. Lung Cancer. 2002. PMID: 12399127 Clinical Trial.

4

Transforming growth factor-beta released by PPD-presenting malignant mesothelioma cells inhibits interferon-gamma synthesis by an anti-PPD CD4+ T-cell clone.

Valle MT, Porta C, Megiovanni AM, Libener R, Mele L, Gaudino G, Strizzi L, Guida R, Toma S, Mutti L. Valle MT, et al. Among authors: porta c. Int J Mol Med. 2003 Feb;11(2):161-7. Int J Mol Med. 2003. PMID: 12525871

5

Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients.

Porta C, Zimatore M, Bonomi L, Imarisio I, Paglino C, Sartore-Bianchi A, Mutti L. Porta C, et al. Lung Cancer. 2005 Jun;48(3):429-34. doi: 10.1016/j.lungcan.2004.11.015. Epub 2005 Jan 24. Lung Cancer. 2005. PMID: 15893013 Clinical Trial.

6

SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure.

Cacciotti P, Barbone D, Porta C, Altomare DA, Testa JR, Mutti L, Gaudino G. Cacciotti P, et al. Among authors: porta c. Cancer Res. 2005 Jun 15;65(12):5256-62. doi: 10.1158/0008-5472.CAN-05-0127. Cancer Res. 2005. PMID: 15958571

7

New agents in the management of advanced mesothelioma.

Vogelzang NJ, Porta C, Mutti L. Vogelzang NJ, et al. Among authors: porta c. Semin Oncol. 2005 Jun;32(3):336-50. doi: 10.1053/j.seminoncol.2005.02.010. Semin Oncol. 2005. PMID: 15988688 Review.

8

Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma.

Porta C, Mutti L, Tassi G. Porta C, et al. Cancer Chemother Pharmacol. 2007 Jan;59(1):149-50. doi: 10.1007/s00280-006-0243-4. Epub 2006 Apr 25. Cancer Chemother Pharmacol. 2007. PMID: 16636799 Clinical Trial. No abstract available.

9

Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.

Sartore-Bianchi A, Gasparri F, Galvani A, Nici L, Darnowski JW, Barbone D, Fennell DA, Gaudino G, Porta C, Mutti L. Sartore-Bianchi A, et al. Among authors: porta c. Clin Cancer Res. 2007 Oct 1;13(19):5942-51. doi: 10.1158/1078-0432.CCR-07-0536. Clin Cancer Res. 2007. PMID: 17908991 Free article.

10

Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts.

Bertino P, Piccardi F, Porta C, Favoni R, Cilli M, Mutti L, Gaudino G. Bertino P, et al. Among authors: porta c. Clin Cancer Res. 2008 Jan 15;14(2):541-8. doi: 10.1158/1078-0432.CCR-07-1388. Clin Cancer Res. 2008. PMID: 18223230

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

983 results

Search Page

Filters